Expression level of novel tumor suppressor gene FATS is associated with the outcome of node positive breast cancer
- Author:
- No author available
- Journal Title:
- Chinese Medical Journal
- Issue:
- 18
- DOI:
- 10.3760/cma.j.issn.0366-6999.2011.18.018
- Key Word:
- breast cancer;biomarker;tumor suppressor gene;prognosis;fragile-site associated tumor suppressor
Abstract： Background Recently, we reported the identification of a previously uncharacterized and evolutionarily conserved gene, fragile-site associated tumor suppressor (FATS), at a frequently deleted region in irradiation (IR)-induced tumors.However, the role of FATS in breast cancer development and its clinical significance has not been defined. The aim of this study was to determine the role of FA7S in breast cancer development and to evaluate its clinical significance in breast cancer.Methods The expression level of FATS mRNA was determined in 106 breast carcinomas and 23 paired normal breast tissues using quantitative real time reverse transcription-polymerase chain reaction (RT-PCR). The relationship between FATS expression and clinicopathological parameters were also analyzed.Results The mRNA level of FATS was down-regulated in breast cancer compared with paired normal tissues. Low expression of FATS was correlated with high nuclear grade. There was a tendency to a favorable outcome for patients with high expression of FATS (P=0.346). However, low expression of FATS was associated with poor outcome of breast cancer patients with node positive (P=0.011). Furthermore, the mRNA level of FATS showed an independent value in predicting the outcome of breast cancer patients with positive lymph nodes.Conclusion FATS is involved in the carcinogenesis and development of breast cancer and could be a potential biomarker and prognostic factor for breast cancer therapy.
- [1]LI Hui-ping,JI Jia-fu,HOU Kuan-yong,etc.Prediction of recurrence risk in early breast cancer using human epidermal growth factor 2 and cyclin A2[J].2010,(4).
- [2]ZHANG Zhen-huan,Hiroko Yamashita,Tatsuya Toyama,etc.Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on relapse[J].2009,(15).
- [3]D, Maier,D, Comparone,E, Taylor,etc.New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26.[J].1997,15(8).
- [4]Halpin Murphy-P,Harris JR,Mendenhall NP,etc.Consensus Statement on postmastectomy radiation therapy.[J].1999,44(5).
- [5]O, Caffo,C, Doglioni,S, Veronese,etc.Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up.[J].1996,2.
- [6]Raulet D,Gasser S.The DNA damage response, immunity and cancer.[J].2006,16(5).
- [7]A, Goldhirsch,J H, Glick,R D, Gelber,etc.Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.[J].1998,90.
- [8]W S, el-Deiry,J W, Harper,P M, O'Connor,etc.WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.[J].1994,54.
- [9]Moore DH,Shi Q,Thor AD,etc.p(21WAF1/CIP1) expression in breast cancers: associations with p53 and outcome.[J].2000,61(1).
- [10]S, Nagase,H, Yamakawa,S, Sato,etc.Identification of a 790-kilobase region of common allelic loss in chromosome 10q25-q26 in human endometrial cancer.[J].1997,57.
- [11]Arlt MF,Glover TW,Casper AM.Common fragile sites.[J].2003,100(1).
- [12]Xifeng Zhang,Qian Zhang,Jun Zhang,etc.FATS is a transcriptional target of p53 and associated with antitumor activity[J].2010,9(1).
- [13]Balmain A,Li Z,Mao JH,etc.An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis.[J].2010,29(18).
- [14]Joensuu H,Pylkk\u00e4nen L,Toikkanen S.Long-term survival in node-positive breast cancer treated by locoregional therapy alone[J].1998.
- [15]Maggie C U, Cheang,Matt, van de Rijn,Torsten O, Nielsen.Gene expression profiling of breast cancer.[J].2008,3.
- [16]Pusztai L,Iwamoto T.Breast cancer prognostic markers in the post-genomic era.[J].2011,125(3).
- [17]Recht A,Edge SB,Solin LJ,etc.Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology.[J].2001,19(5).
- [18]Newman LA,Mamounas EP.Review of breast cancer clinical trials conducted by the national surgical adjuvant breast project.[J].2007,87(2).
- [19]Jemal,A.,Siegel,R.,Xu,J.,etc.Cancer statistics, 2010[J].2010,60(5).
- [20]Konigsberg R,Rogelsperger O,Jager W,etc.Cell cycle dysregulation influences survival in high risk breast cancer patients.[J].2008,26(7).
- [21]Far DF,Reed SI,Dulic V,etc.Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition.[J].1998,18(1).